Franchina M, DellOro L, Massironi S
Int J Mol Sci. 2025; 26(4).
PMID: 40004001
PMC: 11855540.
DOI: 10.3390/ijms26041536.
Masciangelo G, Campana D, Ricci C, Andrini E, Rakichevikj E, Fusaroli P
Curr Oncol. 2025; 32(2).
PMID: 39996913
PMC: 11854204.
DOI: 10.3390/curroncol32020113.
Massironi S, Gallo C, Coltro L, DellAnna G, Preatoni P, Danese S
J Endocrinol Invest. 2025; .
PMID: 39969798
DOI: 10.1007/s40618-025-02552-1.
van T Veld B, Hackeng W, Luchini C, Brosens L, Dreijerink K
Endocr Pathol. 2025; 36(1):3.
PMID: 39954168
PMC: 11829919.
DOI: 10.1007/s12022-025-09848-1.
Popa S, Golli A, Matei C, Sonei A, Vere C, Cimpeanu R
Diagnostics (Basel). 2025; 15(3).
PMID: 39941267
PMC: 11816404.
DOI: 10.3390/diagnostics15030337.
Successful Treatment of Benign Insulinoma by Transcatheter Angioembolization.
Iriarte-Duran M, Teleche-Loaiza J, Rosero-Guerrero A, Folleco-Pazmino E, Garcia-Trujillo A, Guzman-Gomez G
AACE Clin Case Rep. 2025; 11(1):62-65.
PMID: 39896954
PMC: 11784607.
DOI: 10.1016/j.aace.2024.10.007.
An endoscopic ultrasound-based interpretable deep learning model and nomogram for distinguishing pancreatic neuroendocrine tumors from pancreatic cancer.
Yi N, Mo S, Zhang Y, Jiang Q, Wang Y, Huang C
Sci Rep. 2025; 15(1):3383.
PMID: 39870667
PMC: 11772604.
DOI: 10.1038/s41598-024-84749-7.
[Multimorbid patients in endocrine surgery].
Lorenz K, Braun A, Eisenmann S, Elwerr M, Schneider R
Chirurgie (Heidelb). 2025; 96(2):113-123.
PMID: 39869228
DOI: 10.1007/s00104-024-02224-5.
Novel Surgical Initiatives in Gastroenteropancreatic Neuroendocrine Tumours.
Ritter A, Poppinga J, Steinkraus K, Hackert T, Niessen A
Curr Oncol Rep. 2025; 27(2):157-167.
PMID: 39862354
PMC: 11861007.
DOI: 10.1007/s11912-024-01632-4.
Endoscopic-Ultrasound-Guided Radiofrequency Ablation for Pancreatic Tumors.
Coluccio C, Cappetta S, Romagnoli G, Di Giorgio V, Giuffrida P, Fabbri S
J Clin Med. 2025; 14(2).
PMID: 39860500
PMC: 11765552.
DOI: 10.3390/jcm14020495.
Endoscopic ultrasonography-based intratumoral and peritumoral machine learning ultrasomics model for predicting the pathological grading of pancreatic neuroendocrine tumors.
Mo S, Huang C, Wang Y, Qin S
BMC Med Imaging. 2025; 25(1):22.
PMID: 39827128
PMC: 11743008.
DOI: 10.1186/s12880-025-01555-x.
Progress report on multiple endocrine neoplasia type 1.
Halperin R, Tirosh A
Fam Cancer. 2025; 24(1):15.
PMID: 39826015
PMC: 11742904.
DOI: 10.1007/s10689-025-00440-4.
EUS-radiofrequency ablation for pancreatic neuroendocrine tumors: Is there a promising future?.
Singh S, Suresh Kumar V, Adler D
Endosc Ultrasound. 2025; 13(6):323-324.
PMID: 39802105
PMC: 11723666.
DOI: 10.1097/eus.0000000000000083.
Diagnosis and management of benign secreting pancreatic insulinoma: What's new? 4 case report.
Bahou K, Achour Y, Ilahiane M, Sekkat H, Bakali Y, Mhamdi Alaoui M
Rare Tumors. 2025; 17():20363613241313409.
PMID: 39790868
PMC: 11713962.
DOI: 10.1177/20363613241313409.
Diagnostic and prognostic biomarkers for pancreatic neuroendocrine neoplasms.
Sonnen A, Verschuur A, Brosens L
Pathologie (Heidelb). 2024; 45(Suppl 1):74-82.
PMID: 39556246
DOI: 10.1007/s00292-024-01393-8.
Neuroendocrine tumours and pregnancy: Real-world data from an European Neuroendocrine Tumour Centre of Excellence.
Ratnayake G, Shekhda K, Glover T, Al-Obudi Y, Hayes A, Armonis P
J Neuroendocrinol. 2024; 37(1):e13465.
PMID: 39503166
PMC: 11750320.
DOI: 10.1111/jne.13465.
Single center experience in localization of insulinoma by selective intraarterial calcium stimulation angiography - a case series of 15 years.
Halmi S, Berta E, Dioszegi A, Sira L, Fulop P, Nagy E
Front Endocrinol (Lausanne). 2024; 15:1305958.
PMID: 39497809
PMC: 11532048.
DOI: 10.3389/fendo.2024.1305958.
Molecular Basis of Pancreatic Neuroendocrine Tumors.
Maluchenko A, Maksimov D, Antysheva Z, Krupinova J, Avsievich E, Glazova O
Int J Mol Sci. 2024; 25(20).
PMID: 39456803
PMC: 11507569.
DOI: 10.3390/ijms252011017.
Efficacy of Racecadotril in a Patient Affected by a Therapy-Refractory VIPoma and Carcinoid Syndrome.
Boesenkoetter J, Ellrichmann I, Konukiewitz B, Ellrichmann M, Schulte D
JCEM Case Rep. 2024; 2(10):luae177.
PMID: 39351119
PMC: 11439523.
DOI: 10.1210/jcemcr/luae177.
Glucagon-Producing Pancreatic Neuroendocrine Tumors (Glucagonomas) are Enriched in Aggressive Neoplasms with ARX and PDX1 Co-expression, DAXX/ATRX Mutations, and ALT (Alternative Lengthening of Telomeres).
Mattiolo P, Bevere M, Mafficini A, Verschuur A, Calicchia M, Hackeng W
Endocr Pathol. 2024; 35(4):354-361.
PMID: 39331358
PMC: 11659356.
DOI: 10.1007/s12022-024-09826-z.